Our Science

Epirium is developing novel oral small molecule inhibitors of the enzyme, 15-hydroxyprostaglandin dehydrogenase (15-PGDH), to leverage the repair and rejuvenating potential of Prostaglandin E2 (PGE2) to address significant unmet medical needs. PGE2 has been shown in preclinical studies to have profound beneficial effects on tissue repair, aged muscle function, and resolution of inflammation. 15-PGDH, which is elevated in aged muscle, inactivates PGE2. Epirium is bringing 15-PGDH inhibition to the clinic with a growing pipeline that includes our clinical program to address muscle weakness and loss of function in sarcopenia, as well as a broader preclinical scope of indications that include rare neuromuscular diseases and lung fibrosis.